The clinical value of faecal calprotectin and lactoferrin measurement in postoperative crohn’s disease

United European Gastroenterology Journal

Volumn 3, Issue 1, 2015, Pages 5-10

  Yamamoto, Takayuki ^a  

^a Yokkaichi Hazu Medical Centre   (Japan)

Author keywords

Calprotectin; Crohn s disease; Endoscopic activity; Faecal biomarker; Lactoferrin; Postoperative recurrence; Surgery

Indexed keywords

C REACTIVE PROTEIN; CALGRANULIN; LACTOFERRIN;

COLONOSCOPY; CROHN DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE SEVERITY; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; FOLLOW UP; HUMAN; INFLAMMATION; LEUKOCYTE; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SENSITIVITY AND SPECIFICITY; THROMBOCYTE;

EID: 85006201497     PISSN: 20506406     EISSN: 20506414     Source Type: Journal    
DOI: 10.1177/2050640614558106     Document Type: Review

References (21)

1. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn’s disease. Gastroenterology 1990; 99: 956–963.
2. Yamamoto T, Bamba T, Umegae S, et al. The impact of early endoscopic lesions on the clinical course of patients following ileocolonic resection for Crohn’s disease: A 5-year prospective cohort study. United European Gastroenterol J 2013; 1: 294–298.
3. Kane SV, Sandborn WJ, Rufo PA, et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 2003; 98: 1309–1314.
4. Røseth AG, Fagerhol MK, Aadland E, et al. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992; 27: 793–798.
5. Labaere D, Smismans A, Van Olmen A, et al. Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease. United European Gastroenterol J 2014; 2: 30–37.
6. Lamb CA and Mansfield JC. Measurement of faecal calprotectin and lactoferrin in inflammatory bowel disease. Frontline Gastroenterol 2011; 2: 13–18.
7. Kopylov U, Rosenfeld G, Bressler B, et al. Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease. Inflamm Bowel Dis 2014; 20: 742–756.
8. Lin JF, Chen JM, Zuo JH, et al. Meta-analysis: Fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm Bowel Dis 2014; 20: 1407–1415.
9. Mao R, Xiao YL, Gao X, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: A meta-analysis of prospective studies. Inflamm Bowel Dis 2012; 18: 1894–1899.
10. Orlando A, Modesto I, Castiglione F, et al. The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn’s disease: A comparison with ultrasound. Eur Rev Med Pharmacol Sci 2006; 10: 17–22.
11. Scarpa M, D’Incâ R, Basso D, et al. Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn’s disease. Dis Colon Rectum 2007; 50: 861–869.
12. Lamb CA, Mohiuddin MK, Gicquel J, et al. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn’s disease. Br J Surg 2009; 96: 663–674.
13. Yamamoto T, Shiraki M, Bamba T, et al. Faecal calprotectin and lactoferrin as markers for monitoring disease activity and predicting clinical recurrence in patients with Crohn’s disease after ileocolonic resection: A prospective pilot study. United European Gastroenterol J 2013; 1: 368–374.
14. Lobatón T, Lô pez-García A, Rodríguez-Moranta F, et al. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn’s disease. J Crohns Colitis 2013; 7: e641–e651.
15. Papamichael K, Karatzas P and Mantzaris GJ. Faecal calprotectin but not C-reactive protein (CRP) or Crohn’s Disease Activity Index (CDAI) may predict post-operative endoscopic recurrence of Crohn’s disease. J Crohns Colitis 2013; 7: e700–e701.
16. Lasson A, Strid H, Ohman L, et al. Fecal calprotectin one year after ileocaecal resection for Crohn’s disease – a comparison with findings at ileocolonoscopy. J Crohns Colitis 2014; 8: 789–795.
17. Sorrentino D, Paviotti A, Terrosu G, et al. Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn’s disease. Clin Gastroenterol Hepatol 2010; 8: 591–599.
18. Sorrentino D, Terrosu G, Paviotti A, et al. Early diagnosis and treatment of postoperative endoscopic recurrence of Crohn’s disease: Partial benefit by infliximab – a pilot study. Dig Dis Sci 2012; 57: 1341–1348.
19. Kamm MA, De Cruz PP, Wright EK, et al. Optimising post-operative Crohn’s disease management: Best drug therapy alone versus endoscopic monitoring, disease evolution, and faecal calprotectin monitoring. The POCER study. Presented at: 9th Congress of European Crohn’s and Colitis Organisation. Copenhagen, Denmark, 20–22 February 2014.
20. Moum B, Jahnsen J and Bernklev T. Fecal calprotectin variability in Crohn’s disease. Inflamm Bowel Dis 2010; 16: 1091–1092.
21. Naismith GD, Smith LA, Barry SJ, et al. A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn’s disease. Aliment Pharmacol Ther 2013; 37: 613–621.